Batavia Biosciences Joins the Alliance for Regenerative Medicine 

Batavia Biosciences is excited to announce its new Alliance for Regenerative Medicine (ARM) membership, a premier international advocacy organization that brings regenerative medicines and advanced therapies to patients worldwide.
Batavia Biosciences - Favicon

Batavia Biosciences is excited to announce its new Alliance for Regenerative Medicine (ARM) membership. ARM is a premier international advocacy organization that brings regenerative medicines and advanced therapies to patients worldwide. By joining ARM, Batavia Biosciences is committed to advancing the cell and gene therapy field. 

“By aligning ourselves with the Alliance for Regenerative Medicine, we are strengthening our commitment to the broader cell and gene therapy community. Our primary objective is to help innovators develop and deliver ground-breaking therapies that can change and save lives,” says Peter Abbink, PhD, Managing Director at Batavia Biosciences, Inc., located in Woburn, MA. “Our extensive expertise in bioprocessing makes us a valuable partner in accelerating the journey of these therapies from the lab to the market. We aspire to be a key collaborator in a consortium where we can substantially contribute to enhancing the quality of life for patients and caregivers.” 

Batavia Biosciences has a strong track record of offering state-of-the-art development and manufacturing solutions for viral vectors and is an integral player in the cell and gene therapy field. Through its cutting-edge HIP-Vax® platform technologies and services, Batavia Biosciences facilitates the rapid development and scalable manufacturing of life-changing therapies, while significantly reducing the cost of goods. Innovative bioprocess intensification technologies pave the way for significantly improved production of viral vector products, used in gene therapy and immuno-oncology. 

About The Alliance for Regenerative Medicine 

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and modernize healthcare systems so patients benefit from durable, potentially curative treatments. 

As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations. 

Related

New Test for Rapid and Low-cost Quality Control for Polio Vaccines

Batavia Biosciences has developed a qPCR method that can specifically detect mutations that can accumulate in poliovirus strains during vaccine production. The test demonstrates a sensitivity level highly comparable to current best practices. The novel test has been accepted for publication in the international, peer-reviewed prestigious Vaccine journal.

Viral Vector Production Guide

Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression